| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disord... |
| 14 Oct 2026 |
8-K: Other Events
On October 14, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing plans to initiate an open-label extension (“OLE”) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotr... |
| 05 Oct 2026 |
8-K: Other Events
On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating ... |
| 15 Sep 2026 |
8-K: Other Events
On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100th) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302,... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neu... |
| 25 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 25, 2026, Coya Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were: (i) the election of two Class I directors and (ii) the ratificatio... |
| 12 May 2026 |
8-K: Entry into a Material Definitive Agreement
Coya Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
HOUSTON, TX., May 12, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurod... |
| 02 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Separation and General Release Agreement (“Agreement”) confirms the terms of the separation of Howard Berman’s (“you” or “your”) employment with Coya Therapeutics, Inc. (the “Company”), including the consideration described below in... |
| 16 Mar 2026 |
8-K: Results of Operations and Financial Condition
HOUSTON, TX., March 16, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neur... |
| 30 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Securities Purchase Agreement (this “Agreement”), dated as of January 29, 2026, is being entered into among Coya Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto... |
| 20 Jan 2026 |
8-K: Other Events
On January 20, 2026, Coya Therapeutics, Inc. (the “Company”) issued a letter to its stockholders wherein it announced its cash balance as of December 31, 2025 was $46.8 million (unaudited) with projected cash runway into the second half ... |
| 08 Jan 2026 |
8-K: Other Events
On January 8, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing positive results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in 9 pati... |
| 17 Dec 2025 |
8-K: Other Events
On December 16, 2025, Coya Therapeutics, Inc. (the “Company”) received a $4.2 million milestone payment under the Development and License Agreement, dated December 5, 2023 (the “DRL Development Agreement”), by and amongst the Company, Dr... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HOUSTON, TX, November 12, 2025 -- Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurod... |
| 27 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Coya Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Lucid Capital Markets, LLC (the “Underwriter”) an aggregate of 3,636,364 authorized but un... |
| 02 Sep 2025 |
8-K: Other Events
On August 29, 2025, Coya Therapeutics Inc. (“Coya”) received a $4.2 million milestone payment from its strategic partner, Dr. Reddy’s Laboratories Ltd. (“DRL”), pursuant to a Development and License Agreement, dated December 5, 2023 (the... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HOUSTON, TX, August 12, 2025 -- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neur... |
| 29 Jul 2025 |
8-K: Other Events
As previously disclosed, on June 30, 2025, Coya Therapeutics Inc. (“Coya”) submitted additional non-clinical data to support the initiation of its Investigational New Drug Application (the “IND”) for the initiation of a planned clinical ... |
| 01 Jul 2025 |
8-K: Other Events
As previously disclosed on July 14, 2024, the U.S. Food and Drug Administration (the “FDA”), requested that Coya Therapeutics Inc. (the “Company”) provide additional non-clinical data to support the initiation of a planned clinical study... |
Loading...